Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
February 03 2010 - 6:00PM
PR Newswire (US)
THE WOODLANDS, Texas, Feb. 3 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX), a biopharmaceutical company
focused on discovering and developing breakthrough treatments for
human disease, announced today that Arthur T. Sands, M.D., Ph.D.,
Lexicon's president and chief executive officer, will present at
the 2010 BIO CEO & Investor Conference in New York on Monday,
February 8, 2010 at 9:30 a.m., Eastern Time. The conference is
hosted by the Biotechnology Industry Organization (BIO) and will
take place from February 8-9, 2010. About BIO CEO & Investor
Conference The BIO CEO & Investor Conference is the largest
independent investor conference focused on publicly-traded
biotechnology companies. The conference provides a forum where
institutional investors, industry analysts, and senior
biotechnology executives have the opportunity to shape the future
investment landscape of the biotechnology industry through
issue-oriented plenary sessions, educational sessions focused on
hot therapeutic areas and key business issues, company
presentations, and one-on-one meetings. About Lexicon Lexicon is a
biopharmaceutical company focused on discovering and developing
breakthrough treatments for human disease. Lexicon currently has
five drug candidates in development for autoimmune disease,
carcinoid syndrome, diabetes, glaucoma and irritable bowel
syndrome, all of which were discovered by Lexicon's research team.
Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has focused
drug discovery efforts on these biologically-validated targets to
create its extensive pipeline of clinical and preclinical programs.
For additional information about Lexicon and its programs, please
visit http://www.lexpharma.com/. Safe Harbor Statement This press
release contains "forward-looking statements," including statements
relating to Lexicon's growth and future operating results,
discovery and development of products, strategic alliances and
intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors,
specifically including those relating to Lexicon's ability to
successfully conduct preclinical and clinical development of its
potential drug candidates, advance additional candidates into
preclinical and clinical development, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Factors Affecting Forward-Looking Statements" and "Risk Factors"
in Lexicon's annual report on Form 10-K for the year ended December
31, 2008, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise. DATASOURCE: Lexicon Pharmaceuticals,
Inc. CONTACT: D. Wade Walke, Director, Corporate Communications of
Lexicon Pharmaceuticals, Inc., +1-281-863-3046, Web Site:
http://www.lexpharma.com/
Copyright